About E3 ubiquitin-protein ligase MYLIP
E3 ubiquitin-protein ligase MYLIP (MYLIP) is a protein
from Homo sapiens identified by UniProt accession
Q8WY64, 445 residues long.
MolForge cross-references it against 0 known binders and
99 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase MYLIP |
| UniProt accession | Q8WY64 |
| Gene | MYLIP |
| Organism | Homo sapiens |
| Length | 445 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (99)
Diseases linked to this target (Open Targets).
- low density lipoprotein cholesterol measurement · score 0.53
- total cholesterol measurement · score 0.50
- apolipoprotein B measurement · score 0.44
- Hypercholesterolemia · score 0.40
- alcohol consumption measurement · score 0.40
- alcohol drinking · score 0.40
- HMG CoA reductase inhibitor use measurement · score 0.38
- physical activity · score 0.32
- response to statin · score 0.32
- hyperlipidemia · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WY64-F1 | alphafold | PREDICTED | 85.76 | — |
Amino-acid sequence (445 residues)
MLCYVTRPDA VLMEVEVEAK ANGEDCLNQV CRRLGIIEVD YFGLQFTGSK GESLWLNLRN RISQQMDGLA PYRLKLRVKF FVEPHLILQE QTRHIFFLHI KEALLAGHLL CSPEQAVELS ALLAQTKFGD YNQNTAKYNY EELCAKELSS ATLNSIVAKH KELEGTSQAS AEYQVLQIVS AMENYGIEWH SVRDSEGQKL LIGVGPEGIS ICKDDFSPIN RIAYPVVQMA TQSGKNVYLT VTKESGNSIV LLFKMISTRA ASGLYRAITE THAFYRCDTV TSAVMMQYSR DLKGHLASLF LNENINLGKK YVFDIKRTSK EVYDHARRAL YNAGVVDLVS RNNQSPSHSP LKSSESSMNC SSCEGLSCQQ TRVLQEKLRK LKEAMLCMVC CEEEINSTFC PCGHTVCCES CAAQLQSCPV CRSRVEHVQH VYLPTHTSLL NLTVI
Explore E3 ubiquitin-protein ligase MYLIP with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets